News
EDSA
4.550
-4.01%
-0.190
Weekly Report: what happened at EDSA last week (0513-0517)?
Weekly Report · 1d ago
Weekly Report: what happened at EDSA last week (0506-0510)?
Weekly Report · 05/13 10:56
Edesa Biotech, Inc. Quarterly Report on Form 10-Q for the Quarter Ended March 31, 2024
Press release · 05/11 07:09
EDSA Stock Earnings: Edesa Biotech Beats EPS for Q2 2024
Edena Biotech reported earnings per share of -58 cents for the second quarter of 2024. The company did not report any revenue for the quarter. Edesa Biotech's earnings were above the analyst estimate for -69 cents per share. The company just reported results.
Investorplace · 05/11 00:53
Edesa Biotech Inc reports results for the quarter ended in March - Earnings Summary
Edesa Biotech Inc reports results for the quarter ended in March. The company reported a quarterly adjusted loss of 58 cents per share. The mean expectation of three analysts was for a loss of 69 cents. Reported revenue was zero; analysts expected zero. Edesa Biotechnology Inc shares had risen by 7.7% this quarter and lost 1.2% this year.
Reuters · 05/10 21:48
Edesa Biotech Advances Clinical Trials, Manages Finances
TipRanks · 05/10 20:38
Edesa Biotech GAAP EPS of -$0.58 beats by $0.11
Edesa Biotech's Q2 GAAP EPS of -$0.58 beats by $0.11. At March 31, 2024, Edesa had cash and cash equivalents of $2.8 million. The company received reimbursement funding from the Canadian government's Strategic Innovation Fund.
Seeking Alpha · 05/10 20:34
Edesa Biotech Q2 EPS $(0.58) Beats $(0.69) Estimate
Benzinga · 05/10 20:19
Edesa Biotech Inc <EDSA.OQ> expected to post a loss of 69 cents a share - Earnings Preview
Edesa Biotech Inc expected to post a loss of 69 cents a share. The company is expected to show change in quarterly revenue when it reports results on May 9. The average analyst rating on the shares is "buy" and the median 12-month price target is $21.00.
Reuters · 05/07 23:28
Weekly Report: what happened at EDSA last week (0429-0503)?
Weekly Report · 05/06 11:02
Weekly Report: what happened at EDSA last week (0422-0426)?
Weekly Report · 04/29 11:08
Weekly Report: what happened at EDSA last week (0415-0419)?
Weekly Report · 04/22 10:59
Weekly Report: what happened at EDSA last week (0408-0412)?
Weekly Report · 04/15 10:51
Edesa Biotech Showcases Innovation at Investor Conference
TipRanks · 04/11 20:37
Weekly Report: what happened at EDSA last week (0401-0405)?
Weekly Report · 04/08 10:56
RPT-BUZZ-PREVIEW: Conagra's shares sag ahead of results early Thurs
Conagra Brands Inc's CAG.N shares down 1.7% at $29.06 on Weds ahead of fiscal Q3 report due Thurs before market open. Wall Street concerned increased use of weight-loss drugs will crimp sales of U.S. Food companies. Analysts expect CAG to post a rev decline of 2.5% in Q3.
Reuters · 04/04 09:00
BUZZ-PREVIEW: Conagra's shares sag ahead of results early Thurs
Conagra Brands Inc's CAG.N shares down 1.7% at $29.06 on Weds ahead of fiscal Q3 report due Thurs before market open. The packaged foods firm's fiscal third quarter results are expected to be down 2.5%. Wall Street concerned increased use of weight-loss drugs will crimp sales.
Reuters · 04/03 17:58
Edesa Biotech Engages Investors at Global Conferences
TipRanks · 04/02 13:38
Weekly Report: what happened at EDSA last week (0325-0329)?
Weekly Report · 04/01 10:54
Weekly Report: what happened at EDSA last week (0318-0322)?
Weekly Report · 03/25 10:56
More
Webull provides a variety of real-time EDSA stock news. You can receive the latest news about Edesa Biotech Inc through multiple platforms. This information may help you make smarter investment decisions.
About EDSA
Edesa Biotech, Inc. is a Canada-based clinical-stage biopharmaceutical company developing various ways to treat inflammatory and immune-related diseases. The Company’s advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. It is evaluating EB05 in a Phase III study as a potential treatment for acute respiratory distress syndrome (ARDS), a life-threatening form of respiratory failure. In addition, the Company is developing an sPLA2 inhibitor, EB01 (daniluromer), as a topical treatment for chronic allergic contact dermatitis (ACD), a common occupational skin condition. It is conducting a Phase II trial of its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. The Company is also developing product candidates for a number of chronic dermatological and inflammatory conditions.